Most Recent Articles by Steve Duffy
A Phase 1 study in healthy volunteers showed a favorable safety profile with no serious adverse events.
This novel agent has low permeability across the blood-brain barrier, which slows its rate of entry into the brain and reduces dopamine release.
Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.
Results - including the date you were checked and a list of what you were checked for - can be shared by users through text, e-mail or on dating profiles.
The Company indicated that they will work towards an New Drug Application submission for the treatment in the second half of 2018.